CD274 and non-small cell lung carcinoma: The Japan Lung Cancer Society (JLCS) Guidelines for advanced NSCLC currently outline a personalized approach to treatment based on histology, performance status, age (<75 or ≥75 years), results of programmed death-ligand 1 (PD-L1) testing, and whether actionable genomic alterations are present [7,8,9].